"RDA holds the prospect of providing oncologists with an extremely valuable method for managing the chemotherapy regimens of their breast cancer patients."

Maureen E. Trudeau MD, FRCPC
Head, Division of Medical Oncology/Hematology,
Sunnybrook Health Sciences Centre

Rna Diagnostics Inc. is an early stage company developing personalized medical diagnostics to assist in management of cancer and other disease states.

The company's first product, RNA Disruption Assay™ (RDA™), is a novel test that measures RNA structural dysfunction in cancer cells. RDA can determine whether a particular chemotherapy is working effectively in the patient early in treatment thereby guiding clinical decision making.

Highlights include:

Potential to radically improve the cancer chemotherapy management
Proof of principle established in major multi-centre breast cancer clinical trials
RNA Disruption Assay (RDA) provides significant savings for health system payers
Significant advantages over competing chemotherapy management technologies
Management team led by Dr. Ken Pritzker has extensive experience in medical diagnostics and assay development.